Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01095484 · ClinicalTrials.gov registry record
Named Patient Program With Rotigotine Transdermal System
A clinical trial of Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine, sponsored by UCB Pharma.
- Completed
- Registry status
- 520
- Enrollment target
- 20
- Study locations
NCT01095484 is a study of Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine that has completed, run by UCB Pharma. The registered enrollment target is 520 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT01095484, a study of Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
The named patient program will allow investigators to supply rotigotine transdermal system to patients who have a documented medical necessity to receive treatment with the drug.
Conditions Studied
Interventions
- DRUG Rotigotine patch
Study Locations (20)
California
- 036 - Berkeley
- 024 - Fountain Valley
- 034 - Irvine
- 019 - Los Angeles
- 040 - Orange
- 076 - Sunnyvale
Florida
- 070 - Atlantis
- 002 - Boca Raton
- 031 - Clearwater
- 028 - Largo
- 075 - Ormond Beach
Alabama
- 088 - Birmingham
- 082 - Cullman
- 085 - Fairhope
- 014 - Huntsville
Arizona
- 097 - Gilbert
- 003 - Phoenix
- 044 - Phoenix
Colorado
- 035 - Fort Collins
District of Columbia
- 027 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01095484
The ClinicalTrials.gov registry entry for NCT01095484 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine appearing as the primary indexed condition, and to 1 intervention - of which Rotigotine patch is the first listed.
NCT01095484 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01095484 about?
NCT01095484 is a clinical study titled "Named Patient Program With Rotigotine Transdermal System". The named patient program will allow investigators to supply rotigotine transdermal system to patients who have a documented medical necessity to receive treatment with the drug.
What is the current status of trial NCT01095484?
This trial is currently completed. The enrollment target is 520 participants. The study started on 2008-11. Estimated completion is 2012-12.
What conditions does trial NCT01095484 study?
This clinical trial studies the following conditions: Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine.
What interventions are being tested in trial NCT01095484?
The interventions under investigation include: Rotigotine patch (DRUG).
Who is sponsoring clinical trial NCT01095484?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01095484 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.